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Introduction: Differentiation therapy using all-trans retinoic acid (ATRA) revolutionised the 
treatment of acute promyelocytic leukaemia to the extent this leukaemia is one of the most 
curable with ATRA and anthracycline-based chemotherapy providing cure rates above 80% 
(reviewed in [1]). Isotretinoin is used to treat chronic acne. Here, we examine the information 
described in recent patents and the extent to which new findings are leading towards 
extending retinoid-based differentiation therapy to other cancers and the development of new 
therapies for other disorders. 
Areas covered: A search has been undertaken of the literature and of worldwide patents, filed 
during 2014 to the present time, in regard to synthetic agonists and antagonists of retinoic 
acid receptors and novel compositions for the delivery of these agents. 
Expert opinion: New potential therapeutic applications have been described, including lung, 
breast and head and neck cancers, T cell lymphoma and neurodegenerative, metabolic, 
ophthalmic, muscle and inflammatory disorders. Recent patents have described the means to 
maximise retinoid activity. Two decades of efforts to extend retinoid-based therapies have 
been disappointing and new synthetic retinoids, target diseases and modes of delivery may 
well resolve this long standing issue. 
Highlights 
● There are highly selective agonists for all three RAR subtypes and antagonists except for 
RARβ. 
● The tissue distribution of RAR subtypes is variable and functional redundancy is not the 
case. 
● New patents describe the prospects of extending ATRA-driven differentiation therapy of 
acute promyelocytic leukaemia to other cancers. 
● New patents have examined the prospects of broadening the therapeutic uses of retinoids to 
neurodegenerative, metabolic, ophthalmic, muscle and inflammatory disorders. 
● New drug composition and delivery methods are important to improving the efficacy of 
retinoids. 
 
1. Introduction 
 
Natural retinoids are the ligands to different subtypes of retinoic acid receptors (RARs) and 
retinoid X receptors (RXRs). They are metabolically activated derivatives of vitamin A, 
which is delivered to the body by dietary sources.  Active metabolites include the all-trans-, 
9-cis- and 13-cis-retinoic acids (ATRA, 9cRA and 13cRA, respectively). The predominant 
natural retinoid is ATRA, which is present in most tissues and in blood serum. The one less 
abundant but detectable in almost all tissues is 13cRA. 9cRA is more difficult to detect, and 
the only organ in which currently available methods detect this metabolite is pancreas [2]. 
Retinoic acids play crucial roles in embryonic development and as to the behavior of adult 
tissues. In both these circumstances, retinoids are key modulators of cell growth, 
differentiation and apoptosis through their signaling pathways [3]. The different subtypes of 
RAR, their tissue distribution and the availability of novel synthetic analogues of retinoids 
that selectively agonize and antagonize a RAR subtype underlie the precise therapeutic use of 
retinoids. As outlined below, the tissue expression of subtypes is variable and functional 
redundancy is not the case in regard to the major subtypes.   
 
2. Actions of retinoids via nuclear receptors 
The biological activities of retinoids are mediated in target cells through two different classes 
of nuclear receptors: RARs and RXRs which are encoded by separate sets of genes [4]. There 
are three subtypes of RARs and of RXRs which are designated as α, β and γ. Several 
isoforms are generated by alternative splicing or alternative transcriptional start sites. In 
2006, the International Union of Pharmacology recommended official names for these 
receptors and their subtypes. The agreed names for RARα, RARβ and RARγ are NR1B1, 
NR1B2 and NR1B3, respectively, and for RXRα, RXRβ and RXRγ are NR2B1, NR2B2 and 
NR2B3, respectively. The trivial, and more frequently used, names have been used 
throughout this manuscript. RARs and RXRs differ as to their ligand specificity. ATRA binds 
to and activates RARs and has a similar affinity for all three subtypes. 9cRA binds to and 
activates all three RARs and RXRs with different affinities [5]. The dual activation of RARs 
and RXRs by 9cRA is related to its flexible structure which allows conformational adaptation 
to the different binding pockets [6]. 
 
Like most members of the nuclear receptor superfamily, RARs are ligand activated 
transcription factors. They form heterodimers with RXRs and function as ligand-inducible 
transcription factors by binding to DNA sequences called retinoic acid response elements 
(RARE) within the promoter region of a target gene [5]. Activity of the heterodimer is 
controlled by RAR once ligand is bound; however RXR ligand can increase the 
transcriptional efficiency of the heterodimer [7]. The various isoforms of RAR and RXR 
create numerous receptor combinations. Moreover, the ability of RXRs to form heterodimers 
with numerous other nuclear receptors and to modulate a wide range of specific genes adds 
another level of complexity [8]. RARs can either repress or activate transcription [9,10]. 
Some of them act as repressors of transcription in the absence of the ligand, and upon binding 
of ligand the transcriptional repressors are released from the receptor complex and the 
interface for co-activators becomes accessible. Histone acetylase and RNA polymerase 
belong to the co-activation (CoA) complex, and, therefore, the chromatin structure becomes 
loose and the transcription of the target gene can start [11].  
 
Recent observations suggest that, in addition to RARs, the retinoic acid signaling pathway 
involves the peroxisome proliferator–activated  receptor  β/δ (PPAR β/δ) [12]. PPAR β/δ is a 
subtype of the PPARss which are ligand-activated nuclear receptors that are stimulated by 
small lipophilic ligands [13]. PPAR β/δ is expressed ubiquitously, with high expression 
observed in the brain, adipose tissue, skeletal muscle and skin [14]. Similar to RARs, 
activated PPAR β/δ forms a heterodimer with RXR and binds to specific PPAR response 
elements (PPREs) in the promoter regions of target genes [15]. Therefore, RARs and PPAR 
β/δ can activate different set of target genes and exert opposing activities. It has been shown 
that RARs trigger differentiation, cell cycle arrest and apoptosis [16], while PPAR β/δ 
promotes cell survival and proliferation [17,18]. A dual action of retinoic acid  is related to 
different partitioning inside the cell between the two receptors. This process is regulated by 
the intracellular lipid binding proteins: cellular retinoic acid binding protein II (CRABP-II), 
and fatty acid binding protein 5 (FABP5) which deliver retinoic acid to RARs and PPAR β/δ, 
respectively Thus, the cellular retinoic acid response depends on the CRABP-II/FABP5 ratio 
[19]. 
 
3. Tissue distribution of receptors 
There are important differences as to the tissue distributions of RARs and RXRs. In humans, 
RXRβ is ubiquitously expressed; RXRα is mainly expressed in the liver, lung, muscle, 
kidney, epidermis, and intestine and it is the major subtype in skin; and RXRγ is found in the 
brain, cardiac and skeletal muscle. As for the RARs, RARα has a widespread expression 
pattern. In contrast, RARβ expression is prevalent in neural tissues and hardly detectable in 
skin; and RARγ is expressed predominantly in the skin [20,21]. The distribution of RAR 
subtypes and their isoforms has been studied in different species using a variety of 
techniques. An overview of the distribution of RARs in different organs is presented in Table 
1 and details of these studies are provided in the following sections. Besides physiological 
roles in normal tissues, retinoid receptors also play a role in the development of diseases 
including cancers. Such is often due to mutations, chromosomal translocations, change to the 
level of expression, aberrant post-translational modifications, and epigenetic changes. These 
events result in altered function leading to disruption of homeostasis [22]. The abnormalities 
in retinoid signaling have been related mostly to dysregulation of RARα and RARβ [23]. 
 
4. Subtypes and isoforms of retinoic acid receptors and their tissue distribution 
 
4.1. Retinoic acid receptor α 
 
The RARA gene is located on chromosome 17 and is composed of 10 exons and two 
promoters that give rise to the two isoforms RARα1 and RARα2 [24]. RARα1 has a broad 
tissue distribution, including the liver, spleen, kidney, prostate, spinal cord, cerebral cortex, 
uterus, ovary, testis and breast, and is considered as a canonical isoform [25]. In contrast, 
RARα2 is expressed in a limited number of tissues, for example, the intestine, lung and liver, 
and appears in the absence of ligand to be a more potent inhibitor of cell differentiation than 
RARα1. Its role in maintaining cells in an undifferentiated stem cell state [26] is seen in 
multiple myeloma whereby RARα2 expression is linked to primary multiple myeloma and 
drug resistance in this disease [27]. 
 
Cells of the hematopoietic system express mostly the RARα and RARγ subtypes and each 
has a specific modulatory role [17]. Although, disruption of any one of these two genes does 
not alter hematopoiesis, RARα deficient mice demonstrated an impaired response to retinoids 
which leads to the accumulation of more immature granulocytes in their bone marrow after 
vitamin A treatment. Thus, RARα can modulate granulopoiesis in response to retinoids [28]. 
Moreover, the double mutant mice RARα−/−RARγ−/− die in utero and, therefore, it is hard to 
conclude whether RARs are needed for adult bone marrow hematopoiesis.  However, 
disruption of both genes affects granulocyte differentiation potential. The double mutant 
RARα1−/−RARγ−/− cells derived from foetal liver were found to be blocked at the 
myelocyte/metamyelocyte stage of myelopoiesis [29]. On the other hand, RARα−/−RARγ−/− 
double mutant cells differentiate faster in response to G-CSF and SCF. These inconclusive 
results may be related to effects on different RARα isoforms and implicate distinctions 
between the functions of RARα1 and RARα2. Oren and co-workers have suggested that 
RARα2 may more effectively inhibit differentiation, and this becomes the predominant 
phenotype in RARα1−/− cells [30]. Nevertheless, Zhu and co-workers demonstrated for 
murine progenitor cells that RARα upregulation is required for optimal differentiation of 
primitive myeloid cells to granulocytes [31] and activity of RARα is altered, by chromosomal 
translocations, in all cases of acute promyelocytic leukaemia (APL). A characteristic of this 
type of leukemia is the leukaemic cells are blocked at the promyelocyte stage of granulocyte 
differentiation [32]. The chromosomal translocation that fuses the PML gene to the RARα 
gene gives rise to the protein PML-RARα which acts as a constitutive transcriptional 
repressor [31]. However, a pharmacological dose of ATRA is able to dissociate co-repressors 
from the PML-RARα bound to DNA to allow activation of transcription and, therefore, the 
differentiation of APL cells into mature granulocytes [33]. Resistance of leukemia cells to the 
differentiating effect of ATRA has also been correlated with aberrant or deficient 
phosphorylation of RARα [34]. Appropriate phosphorylation of RARα is important to 
retinoid signaling and activated RARs provoke signaling via non-genomic pathways by 
activating p38MAPK and its downstream target mitogen and stress-activated kinase 
1(MSK1). These events are required for cell differentiation. Additional disruption of RARα 
has been observed in cells from acute myeloid leukemia (AML) patients whereby histones 
that associate with the RARA2 promoter show a decrease in their overall acetylation and a 
decreased level of dimethylation. These findings reveal that epigenetic changes to the 
landscape of RARA gene are involved in AML pathogenesis [33].   
 
As to the involvement of RARα in carcinomas, some estrogen receptor (ER)-negative breast 
cancer cells are resistant to retinoic acid and these cells have a reduced level of expression of 
RARα; overexpression of RARα can restore ATRA-driven growth inhibition. RARα can also 
participate in estrogen-mediated proliferation as RARα has been shown to be induced by 
estrogens and shares a subset of binding regions with the estrogen receptor and, therefore, can 
be part of the estrogen receptor transcriptional complex [22]. As to ovarian cancer, the level 
of expression of RARα has been correlated with ATRA-driven growth inhibition of ovarian 
cancer cell lines, but not for primary tumors [35]. RARα can act also as an oncogene. This 
occurs in hepatocellular carcinoma whereby in the absence of the corepressor transcriptional 
intermediary factor 1α (TIF1α) oncogenesis correlates with the deregulation of retinoic acid 
signaling [36].  
 
Recently is has been shown that retinoic acid is necessary for the function of the brain and 
new discoveries point to a crucial role in synaptic plasticity, learning and memory behaviors. 
RARα, RARβ and RARγ have been detected in the adult brain. RARα has a widespread 
distribution with high levels in the hippocampus, cerebellum and cortex. In contrast, RARβ 
has a more restricted distribution that includes high levels in the striatum and the spinal cord, 
and RARγ is found at a low level in the hippocampus [37]. Recent findings suggest that age-
related neuron loss, impairment of memory and cognition and even some neurodegenerative 
disorders are related to the disruption of retinoic acid signaling [37]. 
 
4.2. Retinoic acid receptor β 
 The RARB gene is located on chromosome 3 [38]. It is composed of 13 exons and 4 promoter 
regions which give rise to five distinct isoforms [39]. Expression of RARβ is rapidly induced 
by ATRA whereas expression of RARα and RARγ is sustained within cells at relative 
constant levels. In keeping with this observation, a RARE has been identified in the promoter 
region of RARβ2 [40] and   RARα/RXR dimers bind to resulting in  the expression of 
RARβ2 [41]. Differences in the usage of RARB1 and RARB2 promoters and alternative 
splicing give rise to the major RARβ isoforms β1, β2, and β4, and additional isoforms, such 
as RARβ5 and RARβ1', have been identified [42]. RARβ plays a key role in multiple 
diseases [5] and the various RARβ isoforms have different affinities for ATRA (at least with 
regard to RARβ2 and RARβ4) and different biological functions. For example, the RARβ2 
protein is a tumor suppressor whereas RARβ4 has oncogenic properties [42].  
 
Unlike RARα, the tissue distribution of RARβ is more restricted and it is prevalent in 
epithelial tissues [40] and neural tissue and hardly detectable in skin [23]. RARβ1 is 
considered to be a foetal isoform and plays a crucial role during development [39]. Whereas 
RARβ1 is largely undetectable in adult tissues aberrant expression has been observed in 
several lung-cancer derived cell lines [38]. The recently identified RARβ1’ isoform, which 
arises from an alternative splicing of RARβ1, is expressed in normal lung tissue and 
bronchial epithelial cells and the level of expression is suppressed in human lung cancers that 
are resistant to ATRA. Transfection of ATRA-resistant lung cancer cell lines and bronchial 
epithelial cells with RARβ1’ restored ATRA-sensitivity [43]. These data suggest that 
RARβ1’ plays a critical role in mediating the biological effects of retinoids in relation to 
carcinogenesis and may function as a tumor suppressor which is distinct from the observed 
function of RARβ2 [38,44]. 
 The RARβ2 isoform is the major ATRA-inducible isoform of RAR [42] and it is considered 
as a canonical isoform of RARβ [43]. Loss of RARβ2 activity, especially relating to gene 
hyper-methylation, has been observed in many different types of cancers, including head, 
neck [45] colon [46] non-small lung cancer [47], cervical cancer [44], breast [48] and prostate 
cancer [49]. Other studies have shown that transcriptional deregulation can silence RARβ2 
expression through decreased levels of co-activators, the presence of co-repressors or 
epigenetic mechanisms such as histone deacetylation. Expression of RARβ2 also depends on 
the cellular level of retinoids as to the ATRA-inducible nature of this RAR [42]. Experiments 
in vitro as well as in vivo support the hypothesis that the ATRA growth inhibitory action is 
lost with impaired RARβ2 expression. Berard and co-workers observed a higher incidence of 
pulmonary tumors in a truncated RARβ2 mouse model. The endogenous RARβ2 message 
level was found to be reduced in transgenic lung tissue and further reduced in the tumours 
[50]. Moreover, disruption of RARβ2 in the teratocarcinoma cell line F9 impaired retinoic 
acid–mediated growth inhibition and differentiation [51]. On the other hand, endogenous 
reactivation of the RARβ2 gene, by chromatin remodeling drugs, in breast cancer cell lines 
and xenograft tumors restored retinoic acid–dependent growth inhibition [52]. All of the 
above strongly suggest that RARβ2 acts as tumor suppressor and loss of its expression may 
be an early and common event during malignant progression [41]. 
 
The RARβ4 isoform is a splice variant of RARβ2 and has a distinct functional attribute [53]. 
It lacks a DNA binding domain, and is unable to activate the transcription of target genes. 
Therefore, it has a dominant negative role [54]. ATRA-resistance of breast cancer cells is 
associated with down-regulation of RARβ2 [55] and over-expression of RARβ4. Findings 
from studies of breast cancer cells support the viewpoint that RARβ2 is a potent inhibitor of 
cell proliferation and that RARβ4 interferes with RARβ2-mediated growth suppression upon 
treatment of cells with ATRA [56].  
 
The RARβ5 isoform is similar to RARβ4 and is a splice variant of RARβ2 that lacks the 
domains A and B and part of domain C. RARβ5 is able to form a functional hetero-complex 
with RXRs, but, as is the case for RARβ4, RARβ5 cannot bind to DNA and activate 
transcription of target genes [57]. RARβ5 was initially found in epithelial cells but it is also 
expressed in breast epithelial cells and benign, premalignant and tumor cell lines. Moreover, 
it is preferentially expressed in estrogen-negative breast cancer cells that are resistant to the 
anti-proliferative action of retinoids [57]. 
 
4.3. Retinoic acid receptor γ 
 
The RARG gene is located on chromosome 12. The major portion of the RARγ protein, 
including the DNA and ligand binding domains, is encoded by seven exons that are identical 
for the RARγ1 and RARγ2 isoforms. These isoforms differ only in their N-terminal regions, 
the N-terminal region of RARγ2 shows high homology with that of RARβ and transcription 
of RARγ2 is regulated by its own promoter [58]. Lehmann and colleagues have shown that 
RARγ2, like RARα2 and RARβ2, is activated by retinoids and RARγ1 is not able to drive 
ligand-dependent transcription. The poor transactivation function of RARγ and ability to 
compete for DNA binding suggest that a major function of RARγ1 is to suppress gene 
activation by other RARs [59].  
 
RARγ1 is predominantly expressed in skin where RARγ2 expression is low [60]. Both RARα 
and RARγ show differential expression throughout the epidermal layers whereby expression 
of RARα and RARγ is much higher in the spinous and granular layers in comparison to the 
basal layer of epidermal cells [61]. In the case of keratinocytes, RARγ is considered to be a 
tumor suppressor gene, as RARγ was found to be absent from oral keratinocytes obtained 
from head and neck cancers. In addition, the incidences of premature skin aging and skin 
cancer, induced by ultra-violet radiation, have been correlated to a dramatic decrease in the 
level of RARγ, due to proteasomal degradation of the receptor [22]. RARγ can also act as an 
oncogene. In hepatocellular carcinoma, overexpression of RARγ correlates with an increased 
cell survival through its altered subcellular localization. In this case, there is strong 
cytoplasmic localization of RARγ which interacts with the phosphatidylinositol 3-kinase 
(PI3K) regulatory subunit p85α leading to the activation of the PI3K/Akt pathway, which is 
one of the major survival pathways in cancer cells [62]. 
 
Though RARγ has been found to be mainly expressed in skin, RARγ is viewed as a critical 
regulator of the balance between haematopoietic stem cells (HSC) being able to maintain 
their stem cell status and these cells embarking on differentiation to produce mature blood 
cells [22]. The γ-knockout mouse has a reduced number of HSCs and loss of RARγ also 
abrogated the capacity of ATRA to potentiate the maintenance of HSC in culture [63]. 
Agonizing RARγ appears to promote self-renewal and/or proliferation of HSCs and, as such, 
opposes the ligand-driven action of RARα to drive cells to differentiate. HSCs are still 
present in the knockout mouse and, like RARα, the role of RARγ is modulatory. Further 
evidence to support the notion that RARγ is important to allowing cells to maintain their 
pluripotency comes from studies of the generation of induced pluripotent stem cells (iPSC) 
from somatic cells. The efficiency by which these cells can be generated can be increased by 
the addition of RARγ to the Yamanaka cocktail of transcription factors used to generate iPSC 
[64]. 
 
5. Selective retinoic acid receptor ligands 
Selectivity of ligand binding is conferred by the structure of the receptor’s ligand binding 
domain (LBD). In the case of all RAR subtypes, LBD sequences are conserved as they differ 
only by three amino-acid residues. These differences are responsible for the different 
affinities of natural retinoids to RAR subtypes, and they allow the prospect of synthetic 
retinoids that are selective towards a particular subtype [65]. In the case of nuclear receptors, 
binding of the natural ligand to LBD induces conformational change which facilitates the 
binding of CoAs [66]. LBDs are composed of 12 α-helices and two short β-strands. After 
binding of the activating ligand the most mobile of all helices, helix H12 seals the ligand-
binding cavity and creates the interface for binding of the transcriptional CoAs [65]. Some 
nuclear receptors, for example RARα, act as transcriptional repressors in their un-liganded 
(apo) form. This is due to the short C-terminal part of H10, which adopts a β-strand 
conformation and creates a surface for interaction with transcriptional co-repressors (CoR) 
[67]. Upon binding of agonist, this region adopts a helical structure (H11), and promotes 
displacement of H12 into an active position. However, some synthetic ligands bind to RARs 
with high affinity but fail to stabilize helix H12 in an active position. These ligands are 
classified as partial agonists or antagonists, depending on their ability to prevent CoA 
recruitment. Antagonists not only destabilize the position of helix H12, but also prevent 
natural ligands from binding to LBD [66]. Some RAR antagonists, which are particularly 
efficient in stabilizing the β-strand conformation and favour CoRs binding, are defined as 
inverse agonists [67,68]. The possibility of fine-tuning the responses of particular RAR 
subtype and that isoforms are differentially expressed in tissues allows the therapeutic effects 
of synthetic retinoids to be directed against the required organs, and, accordingly, limit 
unwanted side-effects. 
 
6. Therapeutic Applications of Retinoids 
 
Longstanding interests as to development of the retinoid-based therapies have focussed 
attention to some extent on dysregulation of RAR-mediated signalling in leukaemia and other 
cancers and that skin cells express RARs and the prospect of treating a variety of skin 
disorders. In these two areas, patented developments within the retinoid field have delivered 
significant clinical benefits. Of particular importance is the standard use of ATRA and 
isotretinoin to treat APL and chronic acne, respectively. Recent patented findings bring about 
improvements to these existing applications and anticipate a broadening of the potential 
therapeutic use of retinoids as outlined below. The patents examined in this review are listed 
in Table 2 and structures of compounds are shown in Figure 1. 
 
6.1. Dermatological Conditions 
 
Retinoids are efficacious as to the treatment of dermatological conditions. Isotretinoin 
(13cisRA), an orally administered drug, is successfully used to treat severe forms of acne 
such as acne vulgaris, for which antibiotic and other retinoid treatments have failed. 
However, 13cisRA causes dry skin and  is teratogenic. This retinoid can be given to women 
of child bearing age but contraception has also to be given 1 month before treatment, during 
the treatment and for one month after. Two contraception methods should ideally be 
introduced. Depression has also been associated to a low level with taking 13cRA [69].  
However, this remains controversial [70] and recent studies have contradicted this association 
[71]. Taken together the side effects and patient compliance are restricting factors as to use. 
For some acne sufferers, less toxic retinoids are efficacious. Tazarotene (AGN190168) is a 
cream composition of a RARβγ agonist that was developed by Allergan and alleviates acne in 
many patients. Retinoids are also a common ingredient to many cosmetic creams. Further 
applications of retinoids in dermatology include the use of acitretin, an oral retinoid, in the 
treatment of ichthyosis, lichen planus and psoriasis [72]. Acitretin is teratogenic and, 
therefore, contraception has to be given to women of child bearing age 1 month before 
treatment, during the treatment and for 2 years after. Additionally, the RXR agonist 
bexarotene (LGD-1069) was licenced by the FDA in 2000 for use as an oral and topical 
treatment for cutaneous T-cell lymphomas and its associated lesions [73]. This compound can 
also bind to and activate RARs. Non-hormonal contraception is required in the case of LGD-
1069 because medicament-activation of metabolic enzymes decreases the efficacy of 
hormonal contraception. A concern is that cases of hypothyroidism have been reported in 
patients given LGD-1069  [74,75]. The various retinoid-associated side effects lead to careful 
consideration of patient suitability, compound selection and regular monitoring of patients 
receiving treatment. 
 
There has been little recent advancement with regard to new synthetic retinoids that are RAR 
subtype -selective for dermatological treatments. However, there have been advances 
regarding retinoid boosters. Granger and colleagues had demonstrated the ability of boosters 
to enhance the conversion of retinol and retinyl esters to retinoic acid in drug compositions, 
to enhance drug action [76-85]. More recently, Granger has described compositions of 
retinoid boosters that optimise the synergistic dermatological effects and has provided the 
respective concentrations that are required to maximise retinoid activity [86]. Interestingly, 
one new combination of tazarotene and dapsone (5% w/w), a neutrophil chemotaxis 
suppressant, resulted in a 13% greater reduction in acne associated comedonal lesions as 
compared to tazarotene alone. Additionally, combinations of tazarotene with either 
clindamycin (1% w/w) or benzyl peroxide (5% w/w) provided a 20% reduction in comedonal 
lesions in individuals. 
 
6.2. Cancer  
 
The most clinically significant application of retinoids to date is undoubtedly the use of 
ATRA to treat APL by overcoming the block to cell differentiation in this disease. What was 
once an untreatable illness is no longer so [87]; ATRA is the first in-line treatment for APL 
and often complemented with maintenance chemotherapy in the event of relapse or following 
refractoriness to ATRA. Considering this success and that RARs play an important role in 
regulating cell differentiation, proliferation and survival [88,89], there are ongoing efforts to 
extend ATRA differentiation therapy to other cancers. A limiting factor to use of ATRA to 
treat other cancers is an appreciable level of toxicity which can lead to fatal retinoic acid 
syndrome [90]. Moreover, extending the mechanism of ATRA’s action in APL to other 
cancers is uncertain as to success in APL relates to the specific presence of the PML-RARα 
fusion protein that blocks cell differentiation (see above and [32]). As to both APL and other 
cancers there is a need to develop retinoids that avoid the toxicities associated with ATRA 
and RAR subtype -selective analogues might provide the answer.  
 
Recent findings indicate the use of retinoids in other leukaemias. Churchman and colleagues 
reported recently that alterations to the IKZF1 gene are linked to a stem cell-like phenotype 
and increased cell adhesiveness in BCR-ABL1-associated acute lymphoblastic leukaemia 
pre-B cells [91]. A consequence of these alterations was reduced responsiveness to tyrosine 
kinase inhibitor (TKI) therapy.  A reversal of the stem cell phenotype could be achieved by 
disrupting cell clustering. Four hundred and eighty-three compounds were tested and revealed 
that ATRA, 9cRA, 13cRA and LGD-1069 are potent inhibitors of cellular aggregation, as 
observed by an abrogation of the formation of spheres in Arf-/- BCR-ABL1 IK6-expressing 
pre-B cells. The retinoids and LGD-1069 also selectively induced expression of IKZF1 target 
genes and reduced colony forming potential, with LGD-109 significantly increasing cell 
responsiveness to TKI therapy.  
 There is the potential use of retinoids that are RAR subtype-selective to broaden retinoid 
treatment of cancer as evidenced by abnormal RAR signalling contributing to the 
pathogenesis of various carcinomas. Yan and colleagues have identified elevated levels of 
expression of RARγ in hepatocellular carcinoma cell lines and primary tumours and the 
growth stimulatory effect of such was alleviated by treating these cells with ATRA [62]. 
Also, RARγ has been shown to mediate ATRA-induced growth arrest and apoptosis of 
neoplastic mouse papilloma cell lines. Already, RAR subtype-selective retinoids have 
demonstrated their suitability for the treatment of malignancies other than APL and some are 
non-toxic [92,93]. One group has examined the possible use of retinoids to treat head and 
neck cancer (HNC). HNC comprises of cancers of the lips, larynx, pharynx, oral cavity, nasal 
cavity and treatment largely relies on surgery with the serious associated risks of 
perturbations to speech and the ability to swallow [94]. Previously, the RXR agonist LGD-
1069 has shown potential efficacy in treating human T-cell lymphoma and lung cancer 
[92,93,95], and RARγ agonists in supressing tumour growth in mouse epidermal 
keratinocytes [96]. Gudas and colleagues have tested these agents individually and in 
combination in C57BL/6 mice bearing nitroquinoline-1-oxide (4-NQO)-induced oral cancers 
and significant benefit was observed [97,98]. Notably, gene expression changes induced by 
4-NQO were prevented by LGD-1069 and the RARγ agonist. Additionally, the agents did not 
increase triglycerides and supressed reactive oxygen species production; Gudas suggested 
that these effects aid inhibition of tongue carcinogenesis. As to tumour migration, a 
combination of the above agents led to down-regulation of mRNA levels for a number of 
metallomatrix proteases (MMPs) as well as the protein levels of MMP9, which point to a 
potential strategy for preventing metastasis. The inventors additionally used a tongue 
carcinogenesis model to show that LGD-1069 and CD-1530 inhibited HIF1α signalling, a 
pathway that regulates carcinogenesis, tumour development and migration [99] and 
overexpression of HIF1α, which is known to relate to poor prognosis in HNCs [100]. Further 
indicators of effectiveness included a reduction in the level of β-catenin, which is normally 
increased in oral squamous cell carcinoma [101,102], fewer cancer stem cells within the oral 
cavity and reduced tongue tumour development in general.  
 
In vitro results have indicated the potential efficacy of retinoids in treating breast cancer, but 
this has still to translate to an effective treatment for patients [103]. In contrast, histone 
deacetylase inhibitors (HDACi) have demonstrated efficacy in pre-clinical studies of breast 
cancer [104,105]. Additionally, HDACi have been found to synergise with retinoids to 
suppress the growth of breast cancer cells [106]. Miller and colleagues have created a hybrid 
molecule that is a derivative of TTNN (6-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-
naphthalenyl)-2-naphthalenecarboxylic acid, see Figure 1), which agonises both RARβ and 
RARγ and inhibits histone deacetylase [107]. Hybrid 3 has been shown to have anti-
proliferative effects in vitro against three breast cancer cell lines; MCF-7, SkBr3 and MDA-
MB-231. Interestingly, the molecule was also shown to be active against the BT-20 breast 
cancer line which is double-negative for expression of ER and HER2 and insensitive to 
ATRA. Minimal effects were observed against non-tumour and normal mammary epithelial 
cells creating hope of a potential new treatment for breast cancer which appears not to affect 
normal breast cells.  
 
6.3. Neurodegenerative Disorders 
 
The pathology of Alzheimer’s disease (AD) has been attributed to the deposition of amyloid 
plaque in neurological tissues [108]. The plaques comprise of amyloid β (Aβ) peptides 
[109,110], most of which are either Aβ 1-40 or Aβ 1-42 [111].  Critical to the creation of Aβ 
peptide is the α-, β- and γ-secretase family of cell surface proteolytic enzymes. Sequential 
processing of amyloid precursor protein (APP) by β- and γ-secretases generates the 
pathologic Aβ peptides, whereas APP interaction with α-secretase, prior to β-secretase, yields 
a non-pathologic peptide. A disintegrin and metalloproteinase 10 (ADAM10) is the 
predominant proteolytic enzyme having α-secretase activity [112]. Increasing ADAM10 
levels is, therefore, of interest as a therapeutic approach to AD. Retinol and its derivatives are 
known regulators of Aβ peptide formation and stimulate an increase in α-secretase activity 
[113]. A recent innovative combination of a byrostatin and ATRA, incorporated into a 
microsphere composition, has yielded an increase in α-secretase production in SH-SY5Y 
neuroblastoma cells as compared to bryostatin-1 treatment alone [114]. This novel finding 
points to the potential use of RAR-selective retinoids in combination with a bryostatin-1 for 
the treatment AD to mediate elevation of ADAM10.  
 
There is evidence of a defect in retinoid transport in the brains of Alzheimer’s patients [115] 
and the RAR agonist Am80 has been shown to reduce the level of Aβ in the brain of 5 month 
old APP23 mice [116]. Kawara and co-workers have pursued the avenue followed by Gudas 
and co-workers in the case of HNC [97] and examined the benefit to Alzheimer’s patients of 
an RAR agonist used in combination with an RXR agonist [117]. Previously, LGD-1069 was 
found to enhance apolipoprotein E-dependent Aβ clearance alone [116] and the RAR agonist 
Am80 in addition to the RXR agonist HX630 reduced the level of Aβ significantly and 
strikingly reversed the defects in memory and spatial learning. As to the mechanism of repair, 
likely effectors include increased expression of the Aβ degrading enzymes, insulin degrading 
enzyme (IDE) and nuclear export protein (NEP).  
 
Cell based therapies have been proposed as a non-drug method of promoting repair within the 
brain and neural tissues of individuals affected by neurodegenerative disorders [118]. 
However, there is limited availability of healthy brain tissue for obtaining neural stem cells 
and embryonic and iPSC are seen as an alternative source. Agonizing RARγ is known to 
enhance the frequency of reprogramming of somatic cells to iPSC [64]. The use of iPSC to 
repair neuronal tissue is dependent on the means to drive iPSC towards neuronal 
development. The embodiments of a new patent describe the use of ATRA to induce human 
trophoblast stem (hTS) cells to differentiate into neural cells, creating the potential for in 
vitro testing of drug efficacy and safety and the development of cellular therapies for 
neurodegenerative conditions [119]. Post-treatment of hTS cells with 10μM ATRA, 
dopaminergic neurons, glutamine neurons, serotonergic neurons or GABA (γ- aminobutyric 
acid) neurons expressing the neural markers neurofilament, nestin and glial fibrillary acidic 
protein were obtained. An embryonic or iPSC based therapy has not been licenced for use to 
date, but this development implies a contribution that retinoids might provide to neural cell 
therapies and more broadly to the field of regenerative medicine.  
 
6.4. Metabolic Disorders 
 
The consequences of a high fat diet and/or vitamin A deficiency can be severe. Heart, kidney, 
liver, testes and pancreatic disease, as well as cancer, stroke, and diabetes are some of the 
common complications. The results contained in a recent patent position selective RARβ 
agonists as a potential medicament for such ailments [120]. Following administration of 
retinoids capable of agonizing RARβ, such as; AC261066, AC55649, LE-135, AGN190168, 
CD-271, CD-666, 9cRA, BMS641 and AGN191183 significant improvements to indicators 
of the aforementioned conditions were observed. Notably, in murine models of diabetes and 
other pancreatic diseases, insulin and glucagon sensitivities were either maintained or 
improved, and β-cell degeneration was supressed. In the case of liver disease, decreases in 
alpha smooth muscle actin and hepatic reactive oxygen species as well as suppression of 
hepatic stellate cell activation were observed, highlighting an ability to modulate the 
inflammatory response. The latter was further indicated by a reduction in inflammatory 
markers, such as monocyte chemotractant protein 1 and TNFα. Additionally, RARβ agonist 
treatment was found to increase lethicin:retinol acyltransferase (LRAT) and decrease sterol 
regulatory element binding protein 1c levels in the liver. Of particular note, the highly 
specific RARβ agonist AC261066 led to reduced liver steatosis, indicating a preventative role 
in fat accumulation. The inventors also found that agonism of RARβ could restore vitamin A 
signalling in vitamin A deficient organs such as the liver. Another interesting finding was 
triglyceride levels were not found not to be elevated suggesting a safe way of targeting high 
fat diet associated conditions. One of the long term considered risks with the therapeutic use 
of retinoids has been their tendency to elevate serum triglyceride levels [121-123], leading to 
a risk of heart disease. While this patent describes LE-135 as a RARβ agonist it should be 
noted that a previous report has described the compound as having RARβ antagonist activity 
[124]. 
 
6.5. Graft versus host disease  
 
Graft versus host disease (GVHD) is a complication of allogeneic haematopoietic stem cell 
transplantation in which donor T cells within the graft recognise host antigens as foreign 
resulting in T cell activation. This condition can be fatal, with the three year survival rates for 
grade 1 GVHD being 58% and 30% above grade IV [125].  ATRA regulates T cell 
differentiation in a bimodal manner. Early on post-antigen stimulation of T cells, ATRA 
signalling supresses CD4+ve T cell differentiation towards T regulatory cells and provokes 
differentiation towards T helper 17 (Th17) and, thus, an inflammatory response. In contrast, 
ATRA signalling at a late stage during T cell responses supresses the Th17 pro-inflammatory 
response. Given that vitamin A metabolism is upregulated during GVHD, a heightened level 
of ATRA-driven RARα signalling exacerbates GVHD. That RARα signalling is required for 
acute GVHD [126] means that antagonism of RARα is an interesting approach to 
ameliorating the side effects of or preventing GVHD. The embodiments of a new patent 
describe the use of the RAR selective antagonists, specified in US patents 5952345 and 
5958954, to treat GVHD [127]. Inhibiting ATRA signalling in donor T cells attenuated 
GVHD lethality and importantly allowed the graft versus leukaemia effect to remain. 
Attenuation of ATRA signalling in GVHD patients or in patients immediately prior to 
transplant may, therefore, prove a useful means to manage and/or prevent GVHD. Indicated 
in the patent is that either a RARα or RARγ antagonist may be used, alone or in combination 
with an RXR agonist, to modulate the responsiveness of T cell donor cells. Given the 
bimodal action of selective retinoids in promoting and supressing T cell inflammatory 
responses, a great deal of care will be required to ensure safe manipulation of the T cell 
response.  
 
6.6. Ophthalmic Disorders 
 
Keratoconjuntival disorders are inflammatory conditions that affect the cornea and 
conjunctiva. Defects to either can negatively impact on the other and the damage can be 
serious. Keratoconjunctival disorders follow long delays as to the recovery from ophthalmic 
conditions such as dry eye (sicca), keratitis, infection or corneal ulcers due to a secondary 
injury. Degradation of the stromal element of the corneal parenchymal tissue and particularly 
of collagen type I is a key element of the pathogenesis. The delay in repair and degradation to 
collagen results in scar formation which can obstruct vision. This places the prevention/repair 
of collagen degradation as a key target for therapeutic agents.  
 
ATRA has been shown to promote corneal regeneration, albeit weakly and by a mechanism 
that is as yet unclear. The development of selective RAR agonists that can be used to 
efficiently treat keratoconjunctival disorders and which are safe could have major benefits. 
Kimura and colleagues have observed that the RARγ agonists R-677, CD-437 and BMS961 
display a significant capacity to supress collagen type I degradation when tested against 
rabbit keratinocytes. These agonists were also found to be effective in supressing the collagen 
contraction during corneal cicatrisation and conjunctival cicatrisation [128]. 
 
6.7. Inflammatory Conditions 
 
The precise mechanisms of alcohol induced liver disease (ALD) remain undetermined. 
However, the secretion of inflammatory cytokines, oxidative stress and lipid peroxidation 
toxicity of acetaldehyde are known to perpetuate an inflammatory reaction that results in cell 
apoptosis and tissue fibrosis [129-131]. The three stages of the disease include fatty liver 
disease (FLD), alcohol induced hepatitis (AIH), and finally liver cirrhosis [132]. While FLD 
is reversible with cessation of alcohol intake, inflammation in AIH leads to fibrosis and 
damage to areas normally involved in chemical detoxification, leading to irreversible scarring 
[133]. Finally, cirrhosis occurs often leading to the requirement for a liver transplant in severe 
cases. The prevalence of immune cells such as liver sinusoidal endothelial cells, Kupffer 
cells, dendritic cells, natural killer (NK) cells and natural killer T (NKT) cells in the liver 
[134] and the central role of inflammation in alcohol induced liver damage [135] lead to 
modulation of the immune response as an obvious therapeutic target in ALD. NKT cells are 
capable of promoting and suppressing the immune response and they represent an interesting 
means of regulating inflammation in ALD. In a 2014 patent, RAR selective retinoids and/or 
sulfatides were employed in a mouse model of ALD inflammation to supress the pro-
inflammatory activity of the type 1 NK cells and to activate the type 2 NKT cells [136]. The 
retinoids tested as to their capacity to inhibit the activity of the type 1 NKT cells included 
AGN190168, AGN190129 ATRA, retinol, 9cRA, 13cRA, AM580, AC55649, CD-1530, 
etretinate and acitretin. The investigations showed that injection of isotretinoin during or 
before the period of alcohol consumption was protective of liver damage. In particular, mice 
given a high dose of alcohol experienced increased levels of alanine transaminase (ALT), 
while mice given a high dose of alcohol and ATRA showed no elevation of ALT. 
Additionally, histological examination for steatohepatitis in the liver revealed no evidence of 
fatty liver disease in the mice given ATRA.  
 
Osteoarthritis (OA) results from breakdown to the cartilage lining the joints and to the under-
lying bone. Inflammation of the synovium generally ensues which exacerbates the existing 
pain from bone grinding [137]. The effects of retinoids are known to contribute to pain [138] 
and retinoids are involved in the pathological processes of OA [139]. The use of antagonists 
of RARs has been proposed as a means to alleviate OA-associated pain. To avoid any 
potential toxic effects of pan-antagonists, the inventors of a new patent have used pyrazole 
analogs as RARγ selective antagonists to treat pain in OA [140]. Agonists were tested in the 
knee joints of rats in which the inflammatory agent monosodium iodoacetate had been 
administered resulting in an acute phase reaction. Using a capacitance test, the level of pain 
measured was found to be significantly inhibited in the rats treated with the analogues. The 
inventors may therefore have developed a method that could help alleviate pain generally, or 
specifically in osteoarthritis patients for whom other available treatments such as non-
steroidal anti-inflammatory drugs have major side effects [141-143].  
 
 
6.8. Muscle Damage 
 
The causes of muscle injury are broad and common contributors include physical injury, 
infection, hypoxia due to vascular disruption and muscular dystrophy. Iwamoto and Pacifici 
have described the promotion of muscle repair by either the systemic or local administration 
of RARγ agonists, or by pre-treatment of stem cells with RARγ agonists prior to 
transplantation to the defect site [144]. The RARγ agonists were of the group consisting; CD-
271, CD-394, CD-437, CD-1530, CD-2247, BMS270394 and BMS189961. Muscle defects 
were generated in mice and the systemic or local administration of RARγ was performed at 
varying time points following the insult. The findings included that CD-1530 greatly 
increased repair to the defects, as compared to control mice in which the repair was largely 
fibrous scar tissue. Further support to the role of RARγ in muscle repair is that agonism of 
RARγ failed to promote acceleration of repair in γ-null mice.  Of the RARγ agonists tested, 
BMS270394 was found to be the most effective. As to the stem cells, pre-treatment of 
mesenchymal stromal cells with a number of RARγ agonists was performed for periods of 
between 12 hours and 72 hours, and treated cells were administered at varying time points 
following muscle injury. Treatment on days 5, 7 and 10 following injury was found to be 
optimal for repair. The identification of treated mesenchymal stromal cells in the repair site 
was possible by DsRed labelling of the cells followed by fluorescent stereomicroscopy of 
histological sections. Overall it was found that local and systemic administration of the RARγ 
agonist BMS270394 enhanced muscle repair, as did mesenchymal stromal cells pre-treated 
with this agonist for 72 hours and cells administered between days 5 and 9 following injury. 
 
7. Drug Composition and Delivery Methods 
 
Appropriate delivery methods are essential to the therapeutic application of selective 
retinoids. A prominent feature of recent retinoid patents has been in regard to drug 
composition and administration. Traditionally retinoids have been delivered either topically 
or orally. While these delivery methods still dominate, alternative applications are being 
developed. One such example has been in relation to the use of expanded 
polytetrafluoroethylene (ePTFE) artificial grafts to treat critical limb ischaemia. A 
complication of stenosis is neointimal hyperplasia and Ameer and colleagues have developed 
a wrap or gel comprising of a biocompatible polymeric matrix and a selective retinoid which 
is placed around a section of a vascular implant [145]. The retinoid diffuses through the 
implant and into the vascular wall and has been seen to stop the proliferation of smooth 
muscle cells and neointimal hyperplasia and up-regulate anti-thrombogenic genes and the 
production of nitric oxide. This represents a promising method of improving the failure rate 
of ePTFE grafts in critical limb ischemia, particularly when healthy autologous vein 
availability is limited. 
 
Retinoids can cause skin irritation when used topically [146]. Formulations of retinoids 
contained within liposomes and solid lipid nanoparticles have been found to be clinically 
equivalent to retinoid gels and the side effects are significantly reduced [147,148]. Despite 
these results, issues with composition stability have limited their development. Patent [149] 
describes a novel composition of retinoids contained within microcapsules that reduces 
irritation and improves the chemical and physical stability of the composition.  A double 
phase retinoid release was also achieved, with the benefit of a reduced initial exposure of the 
skin to retinoids and the maintenance of an effective therapeutic concentration. The employed 
retinoids included ATRA, 13cRA, acitretin, AGN191183, CD-271, AGN190168, retinal and 
etretinate. Another approach that has been used to reduce irritation is the incorporation of a 
retinoid within an aqueous gel suspension. Difficulties in preparing a homogeneous retinoid 
distribution have hindered the use of this technology. However, hydrophobic silica is suited 
to overcoming this limitation [150]. Hydrophobic silica was found to be chemically and 
physically stable and when tested on the flanks of Gottingen mini-pigs, Draize scale test 
results indicated that the composition was non-irritant.  
 
Another invention describes a formulation of retinoids contained within oleosomes. These are 
oily liquid globules which are coated in a layer of lipophilic surfactant, hydrophilic surfactant 
and an anionic surfactant [151]. Retinoids employed in the composition included 3″-tert-
butyl-4′-(2-hydroxyethoxy)-4″-pyrrolidin-1-yl-[1,1′;3′,1″]-terphenyl-4-carboxylic acid. 
Following application of 20µl of the formulation to the ears of BALB/C mice for 7 days, 
indicators of inflammation were examined by clinical observation and measurement of the 
ear thickness. Additional testing of the various formulations included epidermal penetration 
kinetics. A chemically and physically stable slow release formulation, named composition 1, 
provided preferential localisation within the epidermis and controlled retinoid release, and 
importantly maintained a therapeutic concentration. 
   
8. Expert Opinion 
The successful use of ATRA to treat APL demonstrated for the first time differentiation 
therapy of a malignancy that was previously incurable.  An overarching importance of this 
approach to treating cancer is the prospect of milder treatment, alone or when coupled with 
gentler chemotherapy, which is tolerated by very old patients. Twenty three percent of the 
UK population is projected to be aged ≥ 65 by 2034, older patients are often excluded from 
new and aggressive chemotherapy trials and common and intractable fears from toxicity often 
lead to no treatment in very old age as the preferred/advised option. Two decades of 
endeavours have still to make provisions of retinoid-based differentiation therapies for other 
cancers, particularly carcinomas that are prevalent or difficult to treat in old age. Current 
efforts to find a means of extending differentiation therapy are, therefore, important to 
meeting a 21st century societal need. As emphasised below, choosing the right synthetic 
retinoid and targeting the right malignancy, or other disorder, are crucial as different 
synthetic retinoids will be effective for different diseases. 
 
Advances towards extending retinoid-based differentiation therapy to a variety of cancers 
focus on the investigation of novel synthetic retinoids that specifically agonise or antagonise 
a particular retinoid receptor subtype(s). However, highly specific and selective synthetic 
retinoids have been available for quite some time [152], including antagonists [152,153] and, 
in particular, a RARα subtype specific agonist [154]. In keeping, the use of novel synthetic 
retinoids as anti-cancer agents, as opposed to extending the use of ATRA, has been of interest 
for a decade, as brought to attention in 2001 by Altucci and Gronemyer [16]. In the case of 
APL, agonising RARα, as opposed to all RARs by ATRA, is sufficient to differentiate APL 
cells and the use of an agonist of RARα might well avoid ATRA-provoked retinoic acid 
syndrome which can be fatal. However, an agonist of RARα is very unlikely to replace the 
use of ATRA to treat APL. This therapy is highly successful and clinical trial of an RARα 
agonist would be restricted to a relatively small number of patients who have failed 1st and 
2nd line treatments. Therefore, it is encouraging to see the use of retinoids to treat other 
cancers is being explored. The choice of the right synthetic retinoid is crucial as, for example, 
a RARγ agonist and baxarotene have been shown to have a beneficial effect against n4-NQO-
induced oral epidermal cancers in mice and a hybrid molecule which selectively agonises 
RARβ and RARγ and inhibits histone deacetylase has been shown to be effective in vitro 
against breast cancer cell lines. Identifying the right RAR subtype-selective retinoid may 
provide new ways forward to differentiation therapy for malignancies other than APL. 
 
ATRA has long been known to drive differentiation of keratinocytes. Administration of a 
retinoid topically provides a safe form of delivery and, for example, Tazorac® cream, 
containing the RARβγ agonist tazarotene, is a safe and effective treatment for adult and teen 
acne. An interesting way forward to the use of the localised release of retinoids is a patent 
that describes the benefit of placing a wrap/gel containing a selective retinoid around a 
vascular implant to improve the success rate by preventing the proliferation of smooth muscle 
cells. Again the choice of synthetic analogue is crucial: agonizing RARγ is beneficial to 
muscle repair as a recent patent describes a method for muscle regeneration by means of local 
or systemic administration of a RARγ agonist. New methods of delivery and boosters to 
maximise activity, as describe in recent patents, are also important to these possible clinical 
developments. 
 
Cancer and skin disorders have for quite a number of years been seen as targets for retinoid 
therapies. Albeit, retinoids are known to affect a wide variety of cell types and some recent 
patents extend the disease targets of interest in terms of retinoid-based therapies. Applications 
of retinoids to inflammatory, neurodegenerative, metabolic and ophthalmic disorders have 
been patented. The findings indicate a broadening of the possible therapeutic uses of 
retinoids. Moreover and to return to the theme of old age, retinoids may have a future in 
ensuring a health old age by preventing neurodegeneration and the shift in the immune 
system in older people towards an inflammatory profile, termed inflammaging. In this case, a 
chronic production of inflammatory cytokines appears to remodel the system. Whether this 
can be controlled by the systemic administration of an appropriate and safe retinoid is 
particularly interesting. All in all, the prospect of extending the current therapeutic uses of 
retinoids should be viewed as most promising in view of ongoing investigations of new 
synthetic analogues, the combined use of retinoids and other agents and a range of target 
clinical disorders. 
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Figure 1 Structures of selective synthetic ligands for retinoic acid receptors 
 
(B) shows the structures of RAR selective agonists and antagonists employed in patents. For 
comparison the structures of ATRA, 9cRA and 13cRA (A) and RXR selective agonists (C) 
are shown. 
Table 1 Tissue distribution of the RAR subtypes and isoforms. 
 
RAR 
isoform Tissue Technique used Organism 
RARα1 
Overexpressed in  haematopoietic 
cell lines; 
also expressed in: 
kidney, prostate, spinal cord, 
cerebral cortex hepatoma-derived 
cell line, liver, spleen, uterus, 
ovary, haematopoietic 
cell lines 
Northern Blot assay human 
RARα1 Skin – spinous and granular layer Non-radioactive in situ hybridization human 
RARα1 Brain, skin, intestine, muscle, heart, lung, liver, kidney Northern Blot assay mouse 
RARα2 Intestine, lung, liver Northern Blot assay mouse 
RARβ1 
Fetal (kidney, lung, skin) 
Undetectable in heart, colon, 
muscle, lung, spleen from adult 
RNase protection 
assay human 
RARβ1’ ATRA-resistant human lung cancer cell lines 
PCR, 
immunoblotting human 
RARβ2 
epithelial tissues, cancer lung 
tissue 
neural tissue 
RNAase protection 
assay, Southern blot 
analysis and 
Northern Blot assay 
human 
RARβ2 
High: Kidney, prostate, spinal 
cord, cerebral cortex hepatoma-
derived cell line 
Average: liver, spleen, uterus, 
ovary, 
Undetectable in: haematopoietic 
cell lines 
Northern Blot assay human 
RARβ4 Breast cancer Northern Blot assay, RT-PCR human 
RARβ5 normal, premalignant, and malignant breast epithelial cells 
RT-PCR, Western 
Blot human 
RARγ Skin – spinous and granular layer Non-radioactive in situ hybridization human 
RARγ1 Skin - the predominant isoform Northern Blot assay mouse 
RARγ2 Skin – very low level (<5%) Northern Blot assay mouse 
 
 
 
 
 
Table 2 Examples of retinoid compounds employed in patents from 2014 to the present time. 
 Number & Patent  Chemical Name Compound Name 
US20140050676A1  
“Method for treating skin with 
retinoids and retinoid boosters” 
2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohexen-1-yl)nona-2,4,6,8-
tetraenoic acid  
AGN100335/Tretinoin 
(all-trans-retinoic acid), 
pan-RAR agonist 
WO2015138354A1 “Combination 
therapy for head and neck cancer” 
4-(6-Hydroxy-7-tricyclo[3.3.1.13,7]dec-1-
yl-2-naphthalenyl)benzoic acid 
CD-1530, RARγ agonist 
 
US20140051760A1  
“Hybrid molecule having mixed 
retinoic acid receptor agonism and 
histone deacetylase inhibitory 
properties” 
6-(5,5,8,8-tetramethyl-6,7-
dihydronaphthalen-2-yl)naphthalene-2-
hydroxamic acid 
 
SR3957/TTNN hybrid 3 
molecule, RAR agonist 
WO2014085494 
“Combination therapeutics and 
methods for the treatment of 
neurodegenerative and other 
diseases” 
 A retinoid derived from 
the group; AGN100335, 
retinol, retinol acetate, 
retinol palmitate, 13-cis- 
retinoic acid, and LGD-
1069 
WO2014199905A1 
 
“Medicament for treatment of 
alzheimer's disease” 
 
4-[[(5,6,7,8-Tetrahydro-5,5,8,8-
tetramethyl-2-
naphthalenyl)amino]carbonyl]benzoic acid  
Am80, RARα agonist 
 
4-(7,8,9,10-Tetrahydro-7,7,10,10-
tetramethylbenzo[b]naphtho[2,3-
f][1,4]thiazepin-12-yl-benzoic acid 
HX630, RXR pan 
agonist 
CN103561751 “Generation of 
neural stem cells from human 
trophoblast stem cells” 
2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohexen-1-yl)nona-2,4,6,8-
tetraenoic acid  
AGN100335/Tretinoin 
(all-trans-retinoic acid), 
pan-RAR agonist 
WO2014113695A1  
“Methods of treating diseases 
associated with high fat diet and 
vitamin a deficiency using 
retinoic acid receptor agonists” 
4-[4-(2-Butoxyethoxy-)-5-methyl-2-
thiazolyl]-2-fluorobenzoic acid 
AC261066, RARβ2 
agonist 
4'-Octyl-[1,1'-biphenyl]-4-carboxylic acid AC55649, RARβ agonist 
4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-
2-naphthalenyl)carboxamido]benzoic acid 
AM580, RARα agonist 
US20140194517A1 
“Treatment of graft-versus-host 
disease disorders using RAR 
antagonists” 
 RARα and/or RARγ 
antagonists (compounds 
not specified) 
EP2918290A1 
 
“Therapeutic agent for 
keratoconjunctive disorders” 
(E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-
5,5,8,8-tetramethyl-5,6,7,8-
tetrahydronaphthalene-2-yl}vinyl)benzoic 
acid 
R-667, RARγ agonist 
6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-
naphthalene acid 
CD-437, RARγ agonist 
3-fluoro-4-[2-hydroxy-2-(5,5,8,8-
tetramethyl-5,6,7, 8-tetrahydronaphthalene-
2-yl)acetylamino]benzoic acid 
BMS961, RARγ agonist 
US20140187504A1  
“Prevention and treatment of 
inflammatory conditions” 
6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-
benzothiopyran-6-yl)ethynyl]-3-
pyridinecarboxylic acid ethyl ester 
AGN190168/Tazarotene, 
RARβγ agonist 
US20140275049A1  
“Substituted pyrazole analogues 
as RAR antagonists.” 
 Compound names not 
specified, RARγ 
antagonists 
US20140303223A1  
“Composition and method for 
3-Fluoro-4-[(R)-2-hydroxy-2-(5,5,8,8-
tetramethyl-5,6,7,8-tetrahydro-naphthalen-
BMS270394, RARγ 
agonist 
 muscle repair and regeneration” 2-yl)-acetylamino]-benzoic acid 
4-(6-Hydroxy-7-tricyclo[3.3.1.13,7]dec-1-
yl-2-naphthalenyl)benzoic acid 
CD-1530, RARγ agonist 
6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-
ylphenyl)-2-naphthalenecarboxylic acid 
CD-437, RARγ agonist 
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-
naphthoic acid 
CD-271, RARγ agonist 
US201500719841“Controlled and 
localised release of retinoids to 
improve neointimal hyperplasia” 
2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohexen-1-yl)nona-2,4,6,8-
tetraenoic acid  
AGN100335/Tretinoin 
(all-trans-retinoic acid), 
pan-RAR agonist 
US20150190372A1 
“Microcapsules containing 
retinoids, method of preparing 
same, and pharmaceutical 
compositions containing same” 
3″-tert-Butyl-4′-(2-hydroxyethoxy)-4″-
pyrrolidin-1-yl-[1,1′;3′,1″]-terphenyl-4-
carboxylic acid 
 
Company name not 
specified, selectively 
activates RARγ relative 
to the subtypes α and β 
Protected in Patent 
Application 
WO2006066978 
US20150150974A1  
“Aqueous-gel-type topical 
compositions in the form of a 
homogenous suspension of an 
active principle of the class of 
retinoids containing at least one 
hydrophobic silica” 
3″-tert-Butyl-4′-(2-hydroxyethoxy)-4″-
pyrrolidin-1-yl-[1,1′;3′,1″]-terphenyl-4-
carboxylic acid 
 
Company name not 
specified, selectively 
activates RARγ relative 
to the subtypes α and β. 
Protected in Patent 
Application 
WO2006066978 
US20150147403A1 
“Dermatological composition 
comprising oleosomes and 
retinoids, process for preparing 
the same and use thereof” 
3″-tert-butyl-4′-(2-hydroxy-ethoxy)-4″-
pyrrolidin-1-yl-[1,1′;3,1″]-terphenyl-4-
carboxylic acid 
 
Company name not 
specified, selectively 
activates  RARγ relative 
to the subtypes α and β. 
Protected in patent 
application 
WO2006066978 
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